Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...
In the world of oncology drug development, the standard playbook is simple: Race to earlier lines of treatment, where patient populations are larger. But Eli Lilly is flipping that script with its ...
Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to ibrutinib allowed many patients with CLL to stop daily ibrutinib for 1 to 2 years. More than ...
IGHV status significantly influences CLL prognosis, with mutated IGHV linked to longer survival and unmutated IGHV to shorter progression-free survival. NGS enhances IGHV analysis by overcoming Sanger ...
Zanubrutinib significantly improved investigator-assessed PFS compared with acalabrutinib, reducing the risk of progression or death by 32%. “Zanubrutinib is the only [Bruton tyrosine kinase inhibitor ...
Department of Hematology, Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China Background: For patients with chronic lymphocytic leukemia (CLL), the type of nursing ...
Imbruvica is a prescription drug used in adults with chronic lymphocytic leukemia (CLL), a type of cancer that starts in the bone marrow. The drug is available in three oral forms: a capsule, tablet, ...
Copyright: © 2025 The Authors. Published by Elsevier Ltd. We performed a retrospective analysis of patients with CLL registered in the Brazilian CLL Registry between ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with a wide range of clinical presentations that, over time, may or may not require treatment. While a minority of patients require ...
MLR may be a useful marker for assessing activity and progression in chronic lymphocytic leukemia (CLL). Patients with CLL had significantly lower MLR values compared to healthy individuals, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results